PRDM6
Basic information
Region (hg38): 5:123089241-123194266
Links
Phenotypes
GenCC
Source:
- familial patent arterial duct (Supportive), mode of inheritance: AD
- patent ductus arteriosus 3 (Limited), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Patent ductus arteriosus 3 | AD | Cardiovascular | The condition can involve congenital cardiac anomalies, and awareness may allow early management | Cardiovascular | 4284236; 27181681 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PRDM6 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 8 | |||||
missense | 46 | 50 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 4 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 46 | 10 | 7 |
Variants in PRDM6
This is a list of pathogenic ClinVar variants found in the PRDM6 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-123090090-C-T | PRDM6-related disorder | Uncertain significance (Jun 08, 2023) | ||
5-123090093-T-C | Inborn genetic diseases | Uncertain significance (Mar 31, 2024) | ||
5-123090099-C-T | Inborn genetic diseases | Uncertain significance (Aug 02, 2021) | ||
5-123090112-G-C | Inborn genetic diseases | Uncertain significance (Feb 28, 2023) | ||
5-123090126-A-G | Inborn genetic diseases | Likely benign (Jul 22, 2022) | ||
5-123090135-G-C | Inborn genetic diseases | Uncertain significance (Aug 30, 2022) | ||
5-123090137-G-T | PRDM6-related disorder | Benign (Aug 24, 2020) | ||
5-123090139-G-A | Inborn genetic diseases | Uncertain significance (Sep 07, 2022) | ||
5-123090142-T-C | Inborn genetic diseases | Likely benign (Oct 06, 2021) | ||
5-123090146-G-C | PRDM6-related disorder | Benign (Jul 16, 2019) | ||
5-123090154-C-G | PRDM6-related disorder | Likely benign (May 25, 2024) | ||
5-123090166-A-AGCC | PRDM6-related disorder | Benign (May 02, 2024) | ||
5-123090166-A-AGCCGCC | Likely benign (May 01, 2023) | |||
5-123090171-C-A | Inborn genetic diseases | Uncertain significance (Mar 11, 2022) | ||
5-123090172-C-T | Inborn genetic diseases | Uncertain significance (Jun 26, 2023) | ||
5-123090175-C-T | Inborn genetic diseases | Uncertain significance (Apr 06, 2022) | ||
5-123090180-C-T | Inborn genetic diseases | Uncertain significance (Nov 09, 2023) | ||
5-123090181-C-CG | PRDM6-related disorder | Benign (Dec 31, 2019) | ||
5-123090182-C-G | Inborn genetic diseases | Likely benign (Aug 08, 2023) | ||
5-123090187-C-G | Inborn genetic diseases | Uncertain significance (Aug 16, 2021) | ||
5-123090187-C-T | Inborn genetic diseases | Uncertain significance (Apr 12, 2024) | ||
5-123090189-C-T | Inborn genetic diseases | Uncertain significance (Dec 08, 2023) | ||
5-123090208-C-G | Inborn genetic diseases | Uncertain significance (May 26, 2024) | ||
5-123090213-G-A | Inborn genetic diseases | Uncertain significance (Jul 14, 2021) | ||
5-123090229-G-T | Inborn genetic diseases | Uncertain significance (Nov 08, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PRDM6 | protein_coding | protein_coding | ENST00000407847 | 7 | 105145 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.608 | 0.392 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.13 | 228 | 281 | 0.810 | 0.0000150 | 3795 |
Missense in Polyphen | 26 | 89.571 | 0.29027 | 1107 | ||
Synonymous | -0.707 | 129 | 119 | 1.08 | 0.00000692 | 1230 |
Loss of Function | 3.68 | 5 | 24.8 | 0.202 | 0.00000148 | 253 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Putative histone methyltransferase that acts as a transcriptional repressor of smooth muscle gene expression. Promotes the transition from differentiated to proliferative smooth muscle by suppressing differentiation and maintaining the proliferative potential of vascular smooth muscle cells. Also plays a role in endothelial cells by inhibiting endothelial cell proliferation, survival and differentiation. It is unclear whether it has histone methyltransferase activity in vivo. According to some authors, it does not act as a histone methyltransferase by itself and represses transcription by recruiting EHMT2/G9a. According to others, it possesses histone methyltransferase activity when associated with other proteins and specifically methylates 'Lys-20' of histone H4 in vitro. 'Lys-20' methylation represents a specific tag for epigenetic transcriptional repression. {ECO:0000250|UniProtKB:Q3UZD5}.;
- Disease
- DISEASE: Patent ductus arteriosus 3 (PDA3) [MIM:617039]: A congenital heart defect characterized by the persistent opening of fetal ductus arteriosus that fails to close after birth. Fetal ductus arteriosus connects the pulmonary artery to the descending aorta, allowing unoxygenated blood to bypass the lung and flow to the placenta. Normally, the ductus occludes shortly after birth. {ECO:0000269|PubMed:27181681}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Lysine degradation - Homo sapiens (human)
(Consensus)
Recessive Scores
- pRec
- 0.0986
Haploinsufficiency Scores
- pHI
- 0.322
- hipred
- hipred_score
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.157
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | High | Medium | High |
Mouse Genome Informatics
- Gene name
- Prdm6
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- regulation of transcription by RNA polymerase II;neurogenesis;histone lysine methylation;negative regulation of transcription, DNA-templated;negative regulation of smooth muscle cell differentiation
- Cellular component
- nucleus
- Molecular function
- RNA polymerase II regulatory region sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;histone-lysine N-methyltransferase activity;chromatin DNA binding;protein homodimerization activity;sequence-specific DNA binding;metal ion binding